MY119567A - Matrix metalloproteinase levels as indicators of endometrial cancer - Google Patents

Matrix metalloproteinase levels as indicators of endometrial cancer

Info

Publication number
MY119567A
MY119567A MYPI98001218A MYPI9801218A MY119567A MY 119567 A MY119567 A MY 119567A MY PI98001218 A MYPI98001218 A MY PI98001218A MY PI9801218 A MYPI9801218 A MY PI9801218A MY 119567 A MY119567 A MY 119567A
Authority
MY
Malaysia
Prior art keywords
matrix metalloproteinase
endometrial cancer
indicators
levels
metalloproteinase levels
Prior art date
Application number
MYPI98001218A
Other languages
English (en)
Inventor
Alexander Lopata
Lois A Salamonsen
Michael A Quinn
Original Assignee
Diagnotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnotech Pty Ltd filed Critical Diagnotech Pty Ltd
Publication of MY119567A publication Critical patent/MY119567A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI98001218A 1997-03-20 1998-03-20 Matrix metalloproteinase levels as indicators of endometrial cancer MY119567A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO5736A AUPO573697A0 (en) 1997-03-20 1997-03-20 Diagnosis of endometrial cancer

Publications (1)

Publication Number Publication Date
MY119567A true MY119567A (en) 2005-06-30

Family

ID=3800039

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98001218A MY119567A (en) 1997-03-20 1998-03-20 Matrix metalloproteinase levels as indicators of endometrial cancer

Country Status (14)

Country Link
US (1) US6607894B1 (https=)
EP (1) EP0979304B1 (https=)
JP (2) JP4183757B2 (https=)
KR (1) KR20010006344A (https=)
CN (1) CN1257550A (https=)
AT (1) ATE331039T1 (https=)
AU (1) AUPO573697A0 (https=)
CA (1) CA2284099C (https=)
DE (1) DE69835010T2 (https=)
ES (1) ES2268767T3 (https=)
MY (1) MY119567A (https=)
NZ (1) NZ337868A (https=)
WO (1) WO1998042865A1 (https=)
ZA (1) ZA982403B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1066408A4 (en) * 1998-03-05 2002-09-25 Diadexus Inc A NEW METHOD FOR DETECTING AND DISPLAYING ENDOMETRIC AND UTERUS CANCER
AUPQ219799A0 (en) 1999-08-13 1999-09-02 R. Lurie Pty Ltd Apparatus for obtaining potological samples
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
DE10217677A1 (de) 2002-04-19 2003-11-06 Bayer Ag Verwendung von Aufhellern zur Herstellung von Streichmassen
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
ES2342394T3 (es) * 2004-07-23 2010-07-06 Centre De Recherche Public De La Sante Supervision de la insuficiencia cardiaca.
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
RU2304782C1 (ru) * 2005-12-28 2007-08-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Способ прогнозирования рецидива эндометриоидной кисты яичника
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20120183976A1 (en) * 2009-04-16 2012-07-19 He Zhou Methods of assessing activity of a polysaccharide composition
CA2767914C (en) * 2009-07-24 2020-02-25 Geadic Biotec, Aie. Markers for endometrial cancer
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
RU2430371C1 (ru) * 2010-04-26 2011-09-27 Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) Способ дифференциальной диагностики и прогноза миомы и рака эндометрия
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
US8455624B2 (en) * 2011-06-03 2013-06-04 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
AU2012312071C1 (en) * 2011-09-22 2017-08-24 Memorial Sloan-Kettering Cancer Center Detecting ovarian cancer
HRP20181726T1 (hr) * 2012-01-31 2018-12-28 SPEISER, Paul Neinvazivno dijagnosticiranje raka
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
US10564162B2 (en) * 2014-07-02 2020-02-18 Bionomics Limited Predictive biomarkers
CA2975737A1 (en) * 2015-02-06 2016-08-11 Quest Diagnostics Investments Llc Compositions and methods for determining endometrial cancer prognosis
WO2017190896A1 (en) * 2016-05-04 2017-11-09 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Mmp9 as marker of endometrial cancer
IN202021002695A (https=) 2020-01-21 2021-07-23
CN112961921B (zh) * 2021-03-26 2022-07-01 中国医学科学院北京协和医院 一种用于判断早期子宫内膜癌预后的制剂及复发风险模型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3940793A (en) * 1992-03-31 1993-11-08 Research Foundation Of The State University Of New York, The Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280106A (en) * 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
WO1994005807A1 (en) * 1992-08-28 1994-03-17 Dickson Robert B Matrix-degrading metalloproteinase
AU6396494A (en) * 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3940793A (en) * 1992-03-31 1993-11-08 Research Foundation Of The State University Of New York, The Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM.J.OBSTET.GYNECOL., VOL 171, NO 2, AUGUST 1994 K. TAMAKOSHI ET AL, PP 478-484 *
NIPPON SANKA FUJINKA GAKKAI ZASSHI-ACTA OBSTETRICA ET GYNAE COLOGICA JAPONICA, VOL 48 NO 8, AUGUST 1996 PP 618-622 *

Also Published As

Publication number Publication date
CA2284099A1 (en) 1998-10-01
JP4183757B2 (ja) 2008-11-19
JP2002501613A (ja) 2002-01-15
ATE331039T1 (de) 2006-07-15
US6607894B1 (en) 2003-08-19
CN1257550A (zh) 2000-06-21
CA2284099C (en) 2010-04-27
ZA982403B (en) 1998-10-21
DE69835010D1 (de) 2006-08-03
EP0979304A4 (en) 2003-06-11
EP0979304A1 (en) 2000-02-16
AUPO573697A0 (en) 1997-04-10
KR20010006344A (ko) 2001-01-26
NZ337868A (en) 2002-05-31
WO1998042865A1 (en) 1998-10-01
JP2007202556A (ja) 2007-08-16
ES2268767T3 (es) 2007-03-16
DE69835010T2 (de) 2007-06-06
EP0979304B1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
MY119567A (en) Matrix metalloproteinase levels as indicators of endometrial cancer
FI953445A0 (fi) Menetelmä nukleiinihappojen herkkään osoitukseen
DE69931910D1 (en) Pränatales screening für downs-syndrom
HK1040533A1 (zh) 监察蛋白脢体抑制剂药物活动的方法
EP0340675A3 (en) Time-resolved fluorimetric detection of lanthanide labeled nucleotides
GB9621129D0 (en) Detecting genetic predisposition to sight-threatening diabetic retinopathy
ES2056790T3 (es) Ensayo para determinar la predisposicion o susceptibilidad a enfermedades asociadas con dna.
IL81695A (en) Quantitative determination of the degree of amplification of genes and/or corresponding messenger rna and reagent kit for performing the determination
CA2269664A1 (en) Diagnostic assay for breast cancer susceptibility
DE3264721D1 (en) Reagent for assaying hydrogen peroxide and method of quantitative assay for hydrogen peroxide
EP0657547A4 (en) METHOD FOR MEASURING ANTITHROMBIN III ACTIVITY AND REAGENT FOR THIS METHOD.
KR960702770A (ko) 귀금속 및 실리카-알루미나를 주성분으로 하는 촉매 및 중질 공급물을 수소 이성질체화시키는 방법(noble metal-and silica/alumina-based catalyst and method for the hydroisomerisation processing of heavy feedstocks)
DK0791073T3 (da) Analysemetode
AU2606800A (en) Methods of determining an increased risk of a woman carrying a downs syndrome
MX9600860A (es) Metodo para detectar polimorfismo de gen p4501a2 de citocromo humano.
WO1999054707A3 (en) Fetal testing for prediction of low birth weight
EP0158224A3 (en) Analysis method and means for detecting esterolytic and/or proteolytic enzymes
BR0007056A (pt) Enzima mutante produtora de nucleosìdeo-5' -fosfato, métodos para a produção de uma enzima mutante produtora de nucleosìdeo-5' -fosfato, de um inibidor para uma enzima fosfatase ou de transfosforilação e de um nucleosìdeo-5' -fosfato, cristais de uma enzima, de fosfatase ácida e de complexo de fosfatase ácida, gene, dna recombinante, e, microorganismo
HU9602558D0 (en) Means for treating auto-immune diseases and method of treatment
AR014969A1 (es) Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen
PT800085E (pt) Rastreio pre-natal para sindrome de down
DE3572511D1 (en) Analysis method and means for detecting esterolytic and or proteolytic enzymes
DE69314633D1 (de) Methoden und Zusammensetzungen um die Sensitivität eine Zellegegen DNA-Zerstörende Agentien zu erhöhen
赵右更 et al. PRENATAL DIAGNOSIS Ⅱ. AMNIOTIC FLUID ACETYLCHOLINESTERASE ISOENZYME PATTERNS AND ALPHA-FETOPROTEIN FOR PRENATAL DIAGNOSIS
Matolcsy The Relation Between the Stress Concentration and Crack Propagation